The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 1: 38 - 42

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.01.007

Feature Reports：Lung cancer

Analysis of common driver gene mutations in 661 cases of non⁃small cell lung cancer in eastern region of Henan Province

  • Yan WANG ,
  • Yajing HE ,
  • Lina HUANG ,
  • Yuwen. ZHANG
Expand
  • Department of Pathology，the First People's Hospital of Shangqiu City，Shangqiu 476000，China

Received date: 2023-08-14

  Online published: 2024-01-24

Fold

Abstract

Objective To analyze the mutation of common driver genes in patients with non?small cell lung cancer （NSCLC） in eastern Henan Province. Methods A retrospective analysis was performed on 661 patients with NSCLC admitted to the First People's Hospital of Shangqiu city from March 2022 to July 2023. Five kinds of gene mutation detection kits （fluorescent PCR） were used for gene detection in all enrolled patients. The relationship between the clinical features and the status of each driver gene was analyzed by statistical methods. Results In the 661 patients with NSCLC， the mutation rates of EGFR， KRAS， ALK， ROS1， PIK3CA， BRAF， HER2， RET， MET14 and NRAS were 47.35%， 9.68%， 5.45%， 1.82%， 2.87%， 1.82%， 1.21%， 0.91%， 0.61% and 0%. Mutations in EGFR， ROS1 and HER2 were more likely to occur in women （P < 0.05）， while KRAS mutations were more common in men （P < 0.05）. The mutation rates of EGFR， KRAS and ALK in adenocarcinoma was significantly higher than that in squamous cell carcinoma and NSCLC. NOS （P < 0.05）， and the mutation rate of PIK3CA in NSCLC.NOS was the highest. The mutation rate of KRAS gene in stage Ⅰ+Ⅱ was significantly higher than that in stage Ⅲ+Ⅳ （P < 0.05）， and there was no significant correlation between other genes and clinical stage. Compared with smokers， the mutation rate of total driver gene was significantly higher in non?smokers （P < 0.05）. EGFR， ALK， PIK3CA， ROS1， BRAF and HER2 were more common in non?smokers （P < 0.05）， while KRAS gene was more common in smokers （P < 0.05）. The mutation rate of 10 driver genes in sediment cell block samples was 78.67%， and the detection rate was significantly higher than that in other types of samples （P < 0.05）. Conclusion Common driver genes such as EGFR， KRAS and ALK are correlated with gender， pathological type， clinical stage and smoking. Qualified samples of sediment cells have obvious advantages for gene detection and could be widely promoted in patients. ARMS?PCR combined detection of 10 genes could be used as the preferred gene detection method for newly diagnosed and treated NSCLC patients.

Key words： non?small cell lung cancer; driver gene; polygenic assay; ARMS?PCR method

Cite this article

Yan WANG , Yajing HE , Lina HUANG , Yuwen. ZHANG . Analysis of common driver gene mutations in 661 cases of non⁃small cell lung cancer in eastern region of Henan Province[J]. The Journal of Practical Medicine, 2024 , 40(1) : 38 -42 . DOI: 10.3969/j.issn.1006-5725.2024.01.007

References

1 OBERNDORFER F ， MULLAUER L . Molecular pathology of lung cancer：current status and perspectives ［J］. Curr Opin Oncol，2018，30（2）：69-76.
2 WU J ， LIN Z . Non-Small Cell Lung Cancer Targeted Therapy： Drugs and Mechanisms of Drug Resistance［J］. Int J Mol Sci. 2022， 23（23）：15056.
3 ZHENG J ， DOU Y ， HUANG D ， et al . Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance［J］. Jpn J Clin Oncol， 2023，hyad123.
4 中华医学会病理学分会，国家病理质控中心，中华医学会肿瘤学分会肺癌学组，等 . 非小细胞肺癌MET临床检测中国专家共识［J］. 中华病理学杂志， 2022，51（11）：1094-1103.
5 中国抗癌协会肿瘤病理专业委员会分子病理协作组，中华医学会病理学分会分子病理学组，国家病理质控中心 . 中国非小细胞肺癌RET基因融合临床检测专家共识［J］. 中华病理学杂志，2021，50（6）：583-591.
6 中华医学会肿瘤学分会，中华医学会杂志社 . 中华医学会肺癌临床诊疗指南（2023版）［J］. 中华肿瘤杂志，2023，45（7）：539-574.
7 ETTINGER D S ， WOOD D E ， AISNER D L ， et al . Non-Small Cell Lung Cancer， Version 3.2022， NCCN Clinical Practice Guidelines in Oncology［J］. J Natl Compr Canc Netw， 2022，20（5）：497-530.
8 苏国苗，王娟，李振辉，等 . 云南地区非小细胞肺癌10种驱动基因突变联合检测分析［J］. 分子诊断与治疗杂志， 2022，14（8）：1292-1295+1299.
9 冯征，文苗苗，王雪娇，等 . 中国西北地区非小细胞肺癌EGFR、ALK、ROS1基因突变和临床病理特征分析［J］. 临床肿瘤学杂志， 2021，26（1）：29-33.
10 陈琳，郭华，孙亚丽，等 . 非小细胞肺癌表皮生长因子受体和ALK基因检测及其与临床病理特征的相关性［J］. 实用医学杂志， 2019，35（11）：1739-1743.
11 邓庆，罗韬，葛佳，等 . 非小细胞肺癌中九基因联合检测突变分析［J］. 临床与实验病理学杂志， 2020，36（6）：666-670.
12 何燕，麻文菁，李进辉，等 . 非小细胞肺癌患者表皮生长因子受体和PIK3CA基因突变与临床病理特征和预后的关系［J］. 中华实用诊断与治疗杂志， 2021，35（6）：576-579.
13 LIN Q ， ZHANG H ， DING H ， et al . The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients ［J］. J Transl Med， 2019，17（1）： 298.
14 PERRONE F ， MAZZASCHI G ， MINARI R ， et al . Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations： Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups［J］. Cancers （Basel）， 2022，14（8）： 2019.
15 HUANG C ， ZOU Q ， LIU H ，et al . Management of non-small cell lung cancer patients with MET exon 14 skipping mutations［J］. Curr Treat Options Oncol， 2020，21（4）： 33.
16 GAINOR J F ， VARGHESE A M ， OU S H ， et al . ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS： an analysis of 1，683 patients with non-small cell lung cancer［J］. Clin Cancer Res， 2013，19（15）： 4273-4281.
17 CAO J ， GU J J ， LIANG Y ， et al . Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing： A Retrospective Study［J］. Technol Cancer Res Treat， 2022， 21：15330338221138213.
18 LEE K C ， KOH J， CHUNG D H ， et al . A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma［J］. J Pathol Transl Med， 2021，55（2）：139-144.
19 LI D ， JIANG H ， JIN F ， et al . Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients［J］. Genes Genomics， 2023，45（1）：93-102.
20 ZHUANG X ， ZHAO C ， LI J ， et al . Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR， ALK， ROS1， KRAS or BRAF ［J］. Cancer Med， 2019，8（6）： 2858-2866.
21 HUANG M H ， LEE J H ， HUNG P S ， et al . Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors［J］. JTO Clin Res Rep， 2022，3（11）：100405.
22 赵冉，伍潇怡，陈颖玮，等 . 二代测序技术检测650例非小细胞肺癌驱动基因突变［J］. 临床与实验病理学杂志， 2022，38（2）：152-156.
23 中华医学会病理学分会，国家病理质控中心，中华医学会肿瘤学分会肺癌学组 等 . 非小细胞肺癌分子病理检测临床实践指南（2021版）［J］. 中华病理学杂志，2021，50（4）：323-332.
24 鲁涛，李强，李岚，等 . 132例晚期非小细胞肺癌胸腔积液EGFR基因突变检测结果及其临床意义：一项来自单中心的回顾性研究 ［J］. 中国肺癌杂志， 2020，23（12）：1059-1065.
25 孙岚，毕阔，刘伟，等 . 非小细胞肺癌患者驱动基因突变及临床病理特征分析［J］. 临床和实验医学杂志， 2022，21（19）：2028-2032.
Options
Outlines

/

〈 〉